Compare TRI & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRI | HLN |
|---|---|---|
| Founded | 1851 | 2022 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Package Goods/Cosmetics |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2B | 43.7B |
| IPO Year | 2002 | N/A |
| Metric | TRI | HLN |
|---|---|---|
| Price | $87.74 | $9.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $158.64 | N/A |
| AVG Volume (30 Days) | 2.9M | ★ 8.2M |
| Earning Date | 04-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.61% | 1.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.87 | $7.04 |
| Revenue Next Year | $7.85 | $4.58 |
| P/E Ratio | ★ $25.72 | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $79.71 | $8.71 |
| 52 Week High | $218.40 | $11.42 |
| Indicator | TRI | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.43 | 34.49 |
| Support Level | $79.71 | $9.59 |
| Resistance Level | $135.03 | $10.00 |
| Average True Range (ATR) | 3.86 | 0.15 |
| MACD | -1.04 | -0.06 |
| Stochastic Oscillator | 0.77 | 8.08 |
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.